scholarly journals F‐18 FDG PET‐CT for response evaluation in head and neck malignancy: Experience from a tertiary level hospital in south India

2021 ◽  
Author(s):  
Justin Benjamin ◽  
Julie Hephzibah ◽  
Nylla Shanthly ◽  
Regi Oommen ◽  
David Mathew ◽  
...  
Keyword(s):  
Head And Neck ◽  
Fdg Pet ◽  
South India ◽  
Tertiary Level ◽  
Response Evaluation ◽  
Head And Neck Malignancy ◽  
Neck Malignancy ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Level Hospital

PO-096: Therapeutic and Prognostic Impact Value of FDG PET/CT in Newly Diagnosed Head and Neck Malignancy

2013 ◽  
Vol 106 ◽  
pp. S41
Author(s):  
R. De Juan Rubio ◽  
P. Cotrina ◽  
R. D'Ambrosi ◽  
O. Hernández ◽  
A.P. Ruiz ◽  
...  
Keyword(s):  
Head And Neck ◽  
Fdg Pet ◽  
Prognostic Impact ◽  
Newly Diagnosed ◽  
Head And Neck Malignancy ◽  
Neck Malignancy ◽  
Pet Ct ◽  
Fdg Pet Ct

18F FDG PET/CT: Normal Variants, Artefacts and Pitfalls in Head and Neck Malignancy

2018 ◽  
pp. 29-42
Author(s):  
Nilendu C. Purandare ◽  
Archi Agrawal ◽  
Sneha Shah ◽  
Venkatesh Rangarajan
Keyword(s):  
Head And Neck ◽  
Fdg Pet ◽  
Normal Variants ◽  
Head And Neck Malignancy ◽  
Neck Malignancy ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals Response evaluation of cervical lymph nodes after chemoradiation in patients with head and neck cancer - does additional [18F]FDG-PET-CT help?

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Daniel Dejaco ◽  
Christian Uprimny ◽  
Gerlig Widmann ◽  
David Riedl ◽  
Patrizia Moser ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Head And Neck ◽  
Predictive Value ◽  
Fdg Pet ◽  
Tumor Board ◽  
Response Evaluation ◽  
Pet Ct ◽  
18F Fdg ◽  
Contrast Ct ◽  
Fdg Pet Ct

Abstract Background Contrast-enhanced high-resolution computed tomography (contrast-CT) is a standard imaging modality following primary concurrent radiochemotherapy (RCT) for response evaluation in patients with head and neck squamous cell carcinoma (HNSCC). We investigated the additional benefit of Fluorine-18-fluorodeoxyglucose ([18F]FDG) - positron emission tomography with computed tomography (PET-CT), if complete response (CR) in the neck based on contrast-CT was considered unsafe by the interdisciplinary tumor board (ITB). Methods In a retrospective observational study, patients recorded in the institutional tumor registry with incident advanced HNSCC following first line treatment with RCT were eligible. If contrast-CT results of the neck were equivocal or positive at response evaluation, a neck dissection (ND) was scheduled. While waiting for the ND, a [18F]FDG-PET-CT was performed in addition. The histopathological outcome of ND served as reference criterion. Accuracy parameters including sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) for both, contrast-CT and PET-CT, served as main outcome parameters. Results A total of 41 HNSCC patients with positive or equivocal posttreatment contrast-CT were eligible for post-RCT-ND. Of these, 33 received an additional [18F]FDG-PET-CT prior to surgery. Median interval between completion of RCT and the ([18F]FDG)-PET-CT was 10 weeks. Vital persistent tumor in the neck was histopathologically found in 13 of 33 patients with positive or equivocal posttreatment contrast-CT. For contrast-CT and [18F]FDG-PET-CT, sensitivity was 92.3 and 69.2% and did not differ statistically significantly (p = 0.250) whereas specificity was significantly higher for [18F]FDG-PET-CT compared with contrast-CT (80% vs. 25%, p = 0.001). For contrast-CT and [18F]FDG-PET-CT accuracy, PPV and NPV was 31.7, 12.0,96.7 and 78.9, 27.8,95.0%, respectively. Conclusion A negative [18F]FDG-PET-CT did not improve the exclusion of persistent vital tumor in the neck after primary RCT in comparison with contrast-CT alone. However, a positive [18F]FDG-PET-CT was a considerably better indicator of persistent, vital tumor in the neck than contrast-CT. If, based on the [18F]FDG-PET-CT result, the ND in patients with an uncertain or positive neck response in contrast CT had been omitted, the treatment of persistent nodal disease would have been delayed in 3 of 13 patients. On the other hand, if ND would have only been performed in [18F]FDG-PET-CT positive patients, an unnecessary ND would have been avoided in 11 of 20 patients.

Response evaluation after chemoradiotherapy for advanced nodal disease in head and neck cancer using diffusion-weighted MRI and 18F-FDG-PET–CT

Oral Oncology ◽  
2015 ◽  
Vol 51 (5) ◽  
pp. 541-547 ◽  
Author(s):  
Charlotte S. Schouten ◽  
Pim de Graaf ◽  
Femke M. Alberts ◽  
Otto S. Hoekstra ◽  
Emile F.I. Comans ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Fdg Pet ◽  
Diffusion Weighted Mri ◽  
Response Evaluation ◽  
Nodal Disease ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Impact of FDG-PET/CT on restaging and response evaluation of locally advanced head and neck cancer patient management

2021 ◽  
pp. 1-10
Author(s):  
Rabab A Moneim ◽  
Emmad Habib ◽  
Radfan Nagi ◽  
M Yasser ◽  
Moustafa Aldaly
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Fdg Pet ◽  
Locally Advanced ◽  
Advanced Head ◽  
Response Evaluation ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Conventional Ct

Abstract Background: Head and neck cancer (HNC) accounts for 5% of all new cancer cases and most were locally advanced. Positron emission tomography/computed tomography (PET/CT) in radiotherapy practice in locally advanced head and neck squamous cell carcinoma (HNSCC) is being used in staging and proper contouring. Proper staging is essential for accurate treatment decision. Methods: This is a prospective phase II study conducted as a single institute centre to evaluate the role of PET/CT-treatment in staging, contouring and response evaluation of 30 patients with locally advanced HNSCC in contrast to CT scan. Our cases did not undergo radical surgery for the primary tumour, and biopsy was taken with PET/CT post-treatment to evaluate response. Results: Median age of patients was 49·4 years (minimum age of 32 years and maximum of 68 years). Males were predominant 22 (73·3%). Nasopharynx was the predominant site 16/30 (53·3%). PET/CT changed the overall staging in 40% of the patients (upstaged in 36·7% and downstaged in 3·3%). Gross tumour volume (GTV) of PET/CT was smaller in 23 patients (76·7%) and larger in 5 (16·7%) than the GTV of conventional CT, whereas GTV of lymph nodes of PET/CT was larger in 20 patients (67·7%) and smaller in 4 (13·3%). PET/CT study detected bone metastasis in two nasopharyngeal carcinoma patients and two cases of 2nd primary tumours which were not detected using conventional CT. The Cox-regression model showed that the median standardised uptake volume (SUV) of the initial tumour had been a dependent predictor of death in patients with HNSCC (p-value = 0·033) where the risk of death was 0·725 times among patients with high SUV of the initial tumour. Consequently, the size of GTV of the tumour was significant in the prediction of death (p = 0·018). Conclusions: 18F-FDG-PET/CT is useful for staging, radiotherapy delineation as well as aiding proper decision making, in addition to assessment of treatment response in HNSCC patients.

scholarly journals Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using 18F-FDG PET/CT: multicenter study for comparison of EORTC, PERCIST, and imPERCIST

2021 ◽  
Author(s):  
Kazuhiro Kitajima ◽  
Tadashi Watabe ◽  
Masatoyo Nakajo ◽  
Mana Ishibashi ◽  
Hiromitsu Daisaki ◽  
...  
Keyword(s):  
Metabolic Disease ◽  
Malignant Melanoma ◽  
Fdg Pet ◽  
Immune Checkpoint Inhibitor ◽  
Metabolic Response ◽  
Checkpoint Inhibitor ◽  
Response Evaluation ◽  
Pet Ct ◽  
Melanoma Patients ◽  
Fdg Pet Ct

Abstract Objective In malignant melanoma patients treated with immune checkpoint inhibitor (ICI) therapy, three different FDG-PET criteria, European Organization for Research and Treatment of Cancer (EORTC), PET Response Criteria in Solid Tumors (PERCIST), immunotherapy-modified PERCIST (imPERCIST), were compared regarding response evaluation and prognosis prediction using standardized uptake value (SUV) harmonization of results obtained with various PET/CT scanners installed at different centers. Materials and methods Malignant melanoma patients (n = 27) underwent FDG-PET/CT examinations before and again 3 to 9 months after therapy initiation (nivolumab, n = 21; pembrolizumab, n = 6) with different PET scanners at five hospitals. EORTC, PERCIST, and imPERCIST criteria were used to evaluate therapeutic response, then concordance of the results was assessed using Cohen’s κ coefficient. Log-rank and Cox methods were employed to determine progression-free (PFS) and overall (OS) survival. Results Complete metabolic response (CMR)/partial metabolic response (PMR)/stable metabolic disease (SMD)/progressive metabolic disease (PMD) with harmonized EORTC, PERCIST, and imPERCIST was seen in 3/5/4/15, 4/5/3/15, and 4/5/5/13 patients, respectively. Nearly perfect concordance between each pair of criteria was noted (κ = 0.939–0.972). Twenty patients showed progression and 14 died from malignant melanoma after a median 19.2 months. Responders (CMR/PMR) showed significantly longer PFS and OS than non-responders (SMD/PMD) (harmonized EORTC: p < 0.0001 and p = 0.011; harmonized PERCIST: p < 0.0001 and p = 0.0012; harmonized imPERCIST: p < 0.0001 and p = 0.0012, respectively). Conclusions All harmonized FDG-PET criteria (EORTC, PERCIST, imPERCIST) showed accuracy for response evaluation of ICI therapy and prediction of malignant melanoma patient prognosis. Additional studies to determine their value in larger study populations will be necessary.

Sign in / Sign up

Export Citation Format

Share Document